Why Aren't IITians Made To Sign Govt Bond Like Doctors? Debate Takes Over Social Media
Last Updated:
ISRO's former Chairman, Dr S Somnath, revealed that over 60% of IIT students walked out midway during ISRO's campus recruitment presentation, simply after seeing the salary figures
A fierce online debate erupted over a deeply rooted inequality in the professional education system; Why are medical graduates bound by long-term service bonds for government jobs, while engineering graduates from prestigious Indian Institutes of Technology (IITs) walk free, often into lucrative private sector roles or foreign companies?
The conversation reignited after a resurfaced statement by ISRO's former Chairman, Dr S Somnath, who lamented the lack of interest shown by IIT students in working with the space research agency. Somnath, who steered the historic Chandrayaan-3 mission, had earlier revealed that over 60% of IIT students walked out midway during ISRO's campus recruitment presentation, simply after seeing the salary figures.
This triggered a strong response from the medical community, particularly from doctors who face mandatory government service bonds lasting up to 10 years after completing degrees like MBBS, MD, or super-specialisations.
Dr Deepak Krishnamurthy, Senior Cardiologist at Bengaluru's KIMS Hospital, questioned the double standards. 'I wonder why only doctors should have bonds to work for govt. Enforce them on IITians also to work for ISRO, DRDO etc," he posted on X (formerly Twitter).
Joining him, Prof Dr G Rajesh of Government Medical College, Kozhikode, said, Let them go to US no issues. But we doctors have bond, upto 10 years in certain states after doing MBBS or MD or superspeciality. Why these guys are exempted? You spend much more money for them!!" He also marked the Prime Minister's Office in his post.
Let them go to US no issues. But we doctors have bond, upto 10 years in certain states after doing MBBS or MD or superspeciality. Why these guys are exempted? You spend much more money for them!! @PMOIndia — Dr G Rajesh (Gopalan Nair Rajesh). (@DrRajeshG1) June 9, 2025
The Indian Institutes of Technology are publicly funded and offer some of the most heavily subsidised education in the country. Despite this, a significant percentage of IIT graduates opt for careers abroad or in private corporations, often ignoring roles in government-funded research bodies such as ISRO or DRDO, where salaries and perks are far less competitive.
The resentment stems from the stark contrast; while MBBS graduates in government colleges may pay as little as Rs 56,000 per year for their studies and are then required to serve in rural or government hospitals, IITians with similar or even greater subsidies face no such obligation.
Dr Somnath's concerns aren't isolated. The country's elite scientific and defence institutions are increasingly finding it difficult to attract top-tier technical talent. Despite ISRO's groundbreaking space missions and DRDO's critical role in defence innovation, these bodies are perceived as offering poor financial incentives and outdated work environments.
The debate has now grown into a wider call for policy reform. Should IIT graduates, who benefit from elite education at nominal cost, be required to serve in government institutions for a few years before heading abroad?
News18's viral page features trending stories, videos, and memes, covering quirky incidents, social media buzz from india and around the world, Also Download the News18 App to stay updated!
First Published:
June 11, 2025, 15:58 IST
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Print
2 hours ago
- The Print
Renalyx Health Systems to invest Rs 800 cr for setting up 3 dialysis machine production units
Currently, the company manufactures RxT 17 through contract manufacturing and with the launch of RxT 21, it will set up its own facilities at Bengaluru and Mysuru in Karnataka and at Mumbai in Maharashtra, Renalyx Health Systems Founder and Director Shyam Vasudeva Rao told PTI. RENALYX – RxT 21 machine is world's first fully indigenous, AI and cloud-enabled smart hemodialysis machine with real-time remote monitoring and clinical connectivity facility, the company said. Mumbai, Jun 11 (PTI) Bengaluru-headquartered Renalyx Health Systems on Wednesday said it is planning to invest Rs 800 crore in the next four years to set up three manufacturing units to produce RENALYX – RxT 21 machine that will help dialysis affordable and accessible to a larger population. This is expected to raise the manpower of the company to over 500 people in 1-2 years from the current 100, he added. 'RxT 21 makes Renalyx the sixth company globally and first in India to produce an advanced dialysis machine with EU CE certification, a mandatory conformity marking for products sold within the European Economic Area (EEA). We are aiming for an annual capacity of 5,000 machines in the company-owned manufacturing units,' he added. The Indian CDSCO (Central Drugs Standard Control Organisation) approval of the machine is in its final stages and is expected by July this year, while the US FDA approval process is underway and anticipated by March 2026, he said. When asked how the company is planning to raise Rs 800 crore for setting up the manufacturing units, Rao said, the company will get it through a mix of foreign direct investment (FDIs), equity and debt. 'The company plans to raise funds through the sale of equity, backed by strong interest from prominent Indian and international investors. In addition, it will raise debt, and the promoters will also invest capital. We are also planning to go public within the next three years,' he added. Renalyx Health Systems is a technology innovation company which is focused on delivering inclusive solutions for comprehensive renal care. With initial deployments of the machine planned in Maharashtra and Karnataka, the company will go for rapid pan-India distribution of RxT 21 with its partners as well as exports to other countries. Rao said the company has penetrated international markets, and has secured orders from South Africa, the USA, and Europe. In India, Renalyx plans to install RxT 21 at primary health centres (PHC), community health centres (CHC), private dialysis centres and hospitals to make renal care available to a large number of people. PTI SM HVA This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
Time of India
2 hours ago
- Time of India
Bharat Biotech in-licences GSK's Shigella vaccine candidate
HYDERABAD: Vaccine maker Bharat Biotech International Limited (BBIL) has in-licenced pharma giant GSK's Shigella vaccine candidate -- altSonflex1-2-3. The vaccine candidate was being developed by GSK against Shigellosis, which is a severe form of bacterial diarrhoea that largely affects children aged five years and below in low- and middle-income countries. While GSK has already conducted Phase-I and II trials in Europe and Africa, Bharat Biotech will be taking up further development with Phase-III clinical trials, regulatory advancement and large-scale manufacturing, Bharat Biotech said on Thursday. As part of the agreement, GSK will continue its support to the programme by assisting with clinical trial design, securing external funding, and contributing to the access and delivery plans and commercialisation strategy. The vaccine has been developed on the innovative generalized modules for membrane antigens (GMMA) based platform, which uses bacterial outer membranes to deliver the O Antigen to the immune system. 'The in-licensed candidate, altSonflex1-2-3, has already shown encouraging results in early-stage clinical trials. A Phase 1 study conducted in Europe demonstrated a favourable safety profile and strong immune response,' the Hyderabad-based vaccine maker said. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Is it better to shower in the morning or at night? Here's what a microbiologist says CNA Read More Undo 'Subsequent Phase 2 trials in Africa, including vaccination of 9-month-old infants—the primary target population—reported no safety concerns. Interim results from 2024 confirmed that the candidate met its pre-set immunogenicity goals,' it added. Bharat Biotech executive chairman Dr Krishna Ella said: 'With no approved vaccine currently available for Shigella and antimicrobial resistance on the rise, there is an urgent need for scalable, science-backed solutions focused on low and middle-income countries. This collaboration combines our strengths in innovation, manufacturing, and global health commitment.' He pointed out that the addition of this vaccine candidate to its portfolio will strengthen Bharat Biotech's already significant presence in vaccines for diarrhoeal infections, including rotavirus, typhoid, polio, non-typhoidal salmonella, cholera, and paratyphi. GSK already has an established relationship with BBIL, after it signed a product transfer agreement for the world's first malaria vaccine, RTS,S, to the Hyderabad-based company in 2021. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Indian Express
3 hours ago
- Indian Express
Between Feb and April, Puneites exposed to ‘unhealthy air' on 60% days
Between February and April this year, Puneites were exposed to unhealthy air for 57 out of 89 days, according to the Centre for Research on Energy and Clean Air (CREA). Researchers analysed data from the Central Pollution Control Board and found the average PM 10 concentration for the month of February was 127 µg/m³. In the month of March as well, the average PM 10 concentration was 112 µg/m³. The safe daily limit for PM 10 concentration under the National Ambient Air Quality Standards (NAAQS) is 100 µg/m³. PM 10 is a coarse particulate matter. Long-term exposure to PM 10 has been linked to an increased risk of respiratory diseases and cardiovascular problems. Pune had worse air quality this April as compared to April 2024, in terms of PM 10 and PM 2.5 concentration. Long-term exposure to PM 2.5, which is a smaller particulate matter, can lead to increased risk of heart disease, reduced lung function and even lung cancer. This underscores the severity and persistence of air pollution in the city, and the alarming fact that air quality is worsening. Biomass combustion and vehicular emissions are the largest source of PM 2.5 in the city, while PM 10 is mainly from road dust, and construction activities. 'As per Portal for Regulation of Air Pollution in Non-Attainment Cities, around Rs 222 crore has been spent under the National Clean Air Programme (NCAP). However, annual PM 10 levels have never met the NAAQS. This calls for a serious revisit of city-level action plans with a focus on accountability and effective on-ground execution,' Manoj Kumar, analyst at CREA) told The Indian Express. 'We have been actively engaging with the local administration on issues like mobility, solid waste management, and crematoria issues but we believe more needs to be done. We are concerned that despite an action plan being implemented for over two years, we still do not meet the national standards. Effective solutions like strengthening public transport, improving walkability etc should be focused on rather than deploying technical solutions like mist fountains or fog cannons that are not evidence-based and proven to be effective. Civil society members and citizens need to be made a part of the process of finding and implementing effective solutions that will address pollution at source,' Dushyant Bhatia, member of the Pune Air Action Hub, said. 'The health impacts of poor air quality go beyond respiratory disorders. While it is known that pollution can cause wheezing, asthma and even lung cancer, what comes as a surprise is that it affects almost every organ in the body and can lead to other disorders. The city should take this issue on priority,' Sharmila Deo from Parisar said. Before the winter months set in and the air quality worsens, Pune still has the opportunity to prioritise actions to improve its baseline air quality. Pune, having both the Metro as well as the PMPML service, experts are encouraging affordable public transport that is more accessible for citizens. Facilitating a modal shift from private vehicles to public transport, and strengthening the implementation of the ban on open burning will largely contribute to pollution mitigation, experts added.
